Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Pharmacokinetics Blood GW786034 (PK) Pazopanib Macular Degeneration MD1103367 - Pharmacokinetics Blood GW786034 (PK)

- 27/09/2021 - 1 Formulário, 1 Grupo de itens, 4 Elementos de dados, 1 Idioma

Grupo de itens: Pharmacokinetics blood

Study part: Pharmacokinetics Blood GW786034 (PK). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Immunogenicity, safety and reactogenicity of combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) in healthy children (100565) - Long-Term Follow-Up (Visit 9, Year 6) - Informed Consent; Demographics; Laboratory Tests; Follow-Up Studies; Tracking Document

- 27/09/2021 - 1 Formulário, 7 Grupos de itens, 29 Elementos de dados, 1 Idioma

Grupos de itens: Administrative, Informed Consent, Demographics, Laboratory Tests, Follow-Up Studies, Tracking Document - Reason for non participation, Investigator signature

Study ID: 100565 Clinical Study ID: 100565 Study Title: An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Phase: phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine Trade Name: Twinrix Study Indication: Hepatitis A; Hepatitis B

Screening Serology GOAL Trial B-cell Lymphoma NCT02499003

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 8 Elementos de dados, 1 Idioma

Grupo de itens: Serology Viral

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Visit: Screening. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Acute Myeloid Leukemia - Treatment Details

- 20/09/2021 - 13 Formulários, 6 Grupos de itens, 39 Elementos de dados, 1 Idioma

Grupos de itens: Therapeutic procedure; Details, Adverse Event, Hemopoietic stem cell transplant, Platelet Engraftment, Neutrophil Engraftment, Therapeutic procedure; Status

Acute Myeloid Leukemia Common Data Elements Holz

Lab: Cytology/Cytogenetics/Cytochemistry

3 Grupos de itens 43 Elementos de dados

Lab: Molecular Genetics, Immunophenotyping, Cytogenetics

1 Grupo de itens 1 Elemento de dados

Physical Examination/Follow-up

4 Grupos de itens 27 Elementos de dados

Lab: Molecular Genetics

1 Grupo de itens 23 Elementos de dados

Mostrar mais

Emotional processing in healthy male volunteers treated with GSK424887 NCT01424384 - Repeat Local laboratory, urinalysis, vital signs, ECG and Pharmacokinetics

- 20/09/2021 - 1 Formulário, 8 Grupos de itens, 58 Elementos de dados, 1 Idioma

Grupos de itens: Local Laboratory, Urinalysis | Local, Vital signs, 12 lead ECG, Electrocardiogram abnormal, Drug Kinetics; Blood, 12 lead ECG | Holter Electrocardiography | Summary Report, Holter Electrocardiography | Electrocardiogram abnormal | Summary Report

Study ID: 105012 Clinical Study ID: NSS105012 Study Title: Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01424384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK424887 Trade Name: Citalopram

(1,3)-ß-D-Glucan CandiSep Anesthesiology and Intensive Care NCT02734550 - (1,3)-ß-D-Glucan

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma

Grupos de itens: beta-1,3-D-glucan, beta-1,3-D-glucan day 1

Study part: (1,3)-ß-D-Glucan. (1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with severe sepsis or septic shock and at high risk of invasive Candida infection (CandiSep). Provided by PD Dr. med. Frank Bloos, Ph.D. Clinic for Anesthesiology and Intensive care, University Clinic Jena.

PCORnet Common Data Model (CDM) - Lab results V4.1

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 29 Elementos de dados, 1 Idioma

Grupo de itens: Lab results CM

Lab results This table is used to store quantitative and qualitative measurements from blood and other body specimens. PCORnet Common Data Model (CDM) The PCORnet Common Data Model (CDM) is a specification that defines a standard organization and representationof data for the PCORnet Distributed Research Network. The PCORnet CDM is a key component of the PCORnet Distributed Research Network (DRN) infrastructure. http://www.pcornet.org/pcornet-common-data-model/

Visit 10 GIMEMA CML0408 NCT00769327 - Visit 10

- 20/09/2021 - 1 Formulário, 12 Grupos de itens, 122 Elementos de dados, 2 Idiomas

Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, FISH (from bone marrow blood), IMATINIB, Molecular Biology (peripheral blood), FISH (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 10 Form

Visit 16 GIMEMA CML0408 NCT00769327 - Visit 16

- 20/09/2021 - 1 Formulário, 11 Grupos de itens, 117 Elementos de dados, 2 Idiomas

Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, FISH (from bone marrow blood), Molecular Biology (peripheral blood), FISH (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 16 Form

Visit 13 GIMEMA CML0408 NCT00769327 - Visit 13

- 20/09/2021 - 1 Formulário, 5 Grupos de itens, 56 Elementos de dados, 2 Idiomas

Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Molecular Biology (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 13 Form

Visit 5 GIMEMA CML0408 NCT00769327 - Visit 5

- 20/09/2021 - 1 Formulário, 4 Grupos de itens, 44 Elementos de dados, 2 Idiomas

Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 5 Form

Visit 7 GIMEMA CML0408 NCT00769327 - Visit 7

- 20/09/2021 - 1 Formulário, 13 Grupos de itens, 127 Elementos de dados, 2 Idiomas

Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, NILOTINIB, FISH (from bone marrow blood), IMATINIB, Molecular Biology (peripheral blood), FISH (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 7 Form

Palavras-chave

Índice

Modelos de dados selecionados